Physician profile
David E Carlson
NPI 1710942859
$4,880.85
in general payments reported to CMS, 2019-2025
33 companies · $1,395 in 2025
The $1,395 reported for 2025 was more than what 77% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $129 · 2020: $633 · 2021: $665 · 2022: $171 · 2023: $1,063 · 2024: $825 · 2025: $1,395.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,282.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,282.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $755.99 | 2020-2025 | General - Therapies, Lux-Dx Insertable Cardiac Monitor, Watchman |
| Novartis Pharmaceuticals Corporation | $415.76 | 2020-2025 | |
| Amgen INC. | $410.21 | 2019-2025 | Repatha, Repatha |
| Edwards Lifesciences Corporation | $378.76 | 2020-2025 | Sapien 3 Ultra Resilia |
| E.R. Squibb & Sons, L.L.C. | $351.16 | 2019-2025 | Opdivo, Camzyos, Eliquis |
| Pfizer INC. | $255.10 | 2019-2025 | |
| Abbott Laboratories | $250.75 | 2019-2025 | Aveir, Amplatzer Amulet, Jot Dx |
| Impulse Dynamics (USA) INC. | $223.23 | 2023-2025 | Optimizer, Optimizer |
| Cvrx, INC. | $212.27 | 2023-2025 | Barostim Neo System |
| Astrazeneca Pharmaceuticals Lp | $200.65 | 2020-2025 | Farxiga, Lokelma |
| Esperion Therapeutics, INC. | $177.15 | 2021-2023 | Nexletol |
| Janssen Pharmaceuticals, INC | $128.95 | 2019-2023 | Xarelto |
| Astellas Pharma US INC | $121.71 | 2020-2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $103.72 | 2023-2025 | Lifevest |
| Alnylam Pharmaceuticals INC. | $98.39 | 2023-2025 | Onpattro |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $92.65 | 2020-2023 | |
| Lexicon Pharmaceuticals, INC. | $82.09 | 2023-2024 | Inpefa |
| Kestra Medical Technology Services, INC. | $76.60 | 2023-2025 | Assure Wcd |
| Boehringer Ingelheim Pharmaceuticals, INC. | $60.53 | 2019-2024 | Jardiance |
| Novo Nordisk INC | $57.98 | 2021-2025 | Wegovy |
| Kiniksa Pharmaceuticals, Ltd. | $56.04 | 2023 | Arcalyst |
| Bridgebio Pharma, INC. | $50.69 | 2025 | Attruby |
| Glaxosmithkline, LLC. | $47.53 | 2025 | Shingrix, Arexvy |
| Bayer Healthcare Pharmaceuticals INC. | $47.17 | 2021-2025 | |
| Inspire Medical Systems, INC. | $42.96 | 2024-2025 | Inspire |
| Regeneron Healthcare Solutions, INC. | $41.60 | 2024 | Evkeeza |
| Sanofi-Aventis U.S. LLC | $28.17 | 2019-2020 | |
| Heartflow, INC. | $23.64 | 2024 | |
| Actelion Pharmaceuticals US, INC. | $22.56 | 2025 | Opsumit, Uptravi |
| Medtronic, INC. | $18.94 | 2025 | Symplicity G3 |
| Merck Sharp & Dohme LLC | $17.30 | 2021 | |
| Scpharmaceuticals INC. | $15.97 | 2024 | |
| Biotronik INC. | $14.63 | 2023 | Biomonitor |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Carlson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.